Ricevi le ultime notizie sulle azioni Actinium Pharma con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di ATNM

Ultime notizie per

Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (Delaware) Common Stock

Actinium Pharmaceuticals Inc

Aligos Therapeutics

Apimeds Pharmaceuticals US, Inc. Common Stock

Apimeds Pharmaceuticals

Actinium Pharma

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

Celularity

Dyadic International, Inc. - Common Stock

Dyadic International

Equillium

Evaxion

FibroGen

Generation Bio

Galecto

Werewolf Therapeutics, Inc. - Common Stock

Werewolf Therapeutics

INmune Bio

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Lantern Pharma

MAIA Biotechnology

Mural Oncology

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

Serina Therapeutics

Skye Bioscience

Senti Biosciences

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Tempest Therapeutics, Inc. - Common Stock

Tempest Therapeutics

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

XOMA Royalty

8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th

Actinium Pharma (ATNM) Previsione

Notizie

Utili

Quote.Nav.option-chain

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Comments

Actinium Pharma Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO